Lukas Biomedical Balance Sheet Health
Financial Health criteria checks 5/6
Lukas Biomedical has a total shareholder equity of NT$280.1M and total debt of NT$82.6M, which brings its debt-to-equity ratio to 29.5%. Its total assets and total liabilities are NT$441.2M and NT$161.1M respectively.
Key information
29.5%
Debt to equity ratio
NT$82.56m
Debt
Interest coverage ratio | n/a |
Cash | NT$31.80m |
Equity | NT$280.13m |
Total liabilities | NT$161.06m |
Total assets | NT$441.19m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6814's short term assets (NT$87.4M) exceed its short term liabilities (NT$57.7M).
Long Term Liabilities: 6814's short term assets (NT$87.4M) do not cover its long term liabilities (NT$103.4M).
Debt to Equity History and Analysis
Debt Level: 6814's net debt to equity ratio (18.1%) is considered satisfactory.
Reducing Debt: 6814's debt to equity ratio has reduced from 41.8% to 29.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6814 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6814 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 2.6% each year.